(19)
(11) EP 2 370 107 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.09.2017 Bulletin 2017/36

(45) Mention of the grant of the patent:
02.08.2017 Bulletin 2017/31

(21) Application number: 09797164.2

(22) Date of filing: 03.12.2009
(51) International Patent Classification (IPC): 
A61K 47/62(2017.01)
C07K 14/485(2006.01)
C07K 14/71(2006.01)
 C07K 14/475(2006.01)
C07K 14/54(2006.01)
C12N 15/62(2006.01)
(86) International application number:
PCT/IB2009/055476
(87) International publication number:
WO 2010/064207 (10.06.2010 Gazette 2010/23)

(54)

SELECTIVE ANTICANCER CHIMERIC PEPTIDE

SELEKTIVES CHIMÄRES ANTIKREBSPEPTID

PEPTIDE CHIMÉRIQUE ANTICANCÉREUX SÉLECTIF

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 03.12.2008 JP 2008309176
09.06.2009 JP 2009138729

(43) Date of publication of application:
05.10.2011 Bulletin 2011/40

(60) Divisional application:
17169343.5
17169346.8

(73) Proprietor: Kawakami, Koji
Shimogyo-ku Kyoto city Kyoto 600-8806 (JP)

(72) Inventors:
  • KOHNO, Masayuki
    Kyoto-shi Kyoto 606-8395 (JP)
  • HORIBE, Tomohisa
    Kyoto 604-8036 (JP)
  • NAKAJIMA, Oumi
    Kyoto 606-8213 (JP)
  • HARAMOTO, Mari
    Kyoto 606-8301 (JP)
  • YANG, Liying
    Kyoto 606-8315 (JP)
  • KAWAKAMI, Koji
    Kyoto 604-8086 (JP)

(74) Representative: Bates, Philip Ian et al
Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street
London E1 8QS
London E1 8QS (GB)


(56) References cited: : 
WO-A2-2008/079973
   
  • SHAW J P ET AL: "Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins." THE JOURNAL OF BIOLOGICAL CHEMISTRY 5 NOV 1991 LNKD- PUBMED:1939154, vol. 266, no. 31, 5 November 1991 (1991-11-05), pages 21118-21124, XP002578726 ISSN: 0021-9258
  • LI ZONGHAI ET AL: "Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US LNKD- DOI:10.1096/FJ.05-4058COM, vol. 19, no. 14, 1 January 2005 (2005-01-01), pages 1978-1985, XP002394913 ISSN: 0892-6638
  • PAPO N, SHAI Y.: "New lytic peptides based on the D, L-amphipathic helix motif preferentially kill tumor cells compared to normal cells", BIOCHEMISTRY, vol. 42, 2003, pages 9346-54,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).